Comment on ‘exploring prognostic factors for survival in patients with advanced pancreatic cancer undergoing PD-1 inhibitor immunotherapy’

Comment on ‘exploring prognostic factors for survival in patients with advanced pancreatic cancer undergoing PD-1 inhibitor immunotherapy’

Saved in:

Bibliographic Details
Main Authors:	Jiaqing Wang, Yi Qin
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	Prognostic factors survival advanced pancreatic cancer PD-1 inhibitor immunotherapy
Online Access:	https://www.tandfonline.com/doi/10.1080/21645515.2024.2405315
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Exploring prognostic factors for survival in patients with advanced pancreatic cancer undergoing PD-1 inhibitor immunotherapy
by: Yue Ma, et al.
Published: (2024-12-01)

HALP score as a prognostic marker for overall survival in advanced pancreatic cancer
by: Nazan Demir, et al.
Published: (2025-04-01)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
by: Miao Wang, et al.
Published: (2021-12-01)

Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy
by: Nan Zhang, et al.
Published: (2025-02-01)

Reversing VTN deficiency inhibits the progression of pancreatic cancer and enhances sensitivity to anti-PD1 immunotherapy
by: Siqi Zhao, et al.
Published: (2025-05-01)

Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models
by: Santeri A. Pakola, et al.
Published: (2025-06-01)

Metabolism of tryptophan in non-small lung cancer patients with different effect of PD-1 / PD-L1 inhibitors immunotherapy
by: E. Yu. Zlatnik, et al.
Published: (2022-06-01)

Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer
by: Hongshu Li, et al.
Published: (2025-04-01)

Prognostic models for survival predictions in advanced cancer patients: a systematic review and meta-analysis
by: Mong Yung Fung, et al.
Published: (2025-03-01)

Prognostic and immunotherapeutic potential of disulfidptosis-associated signature in pancreatic cancer
by: Ran Cui, et al.
Published: (2025-03-01)

Advances in PD-1/PD-L1 pathway inhibitors in the treatment of thyroid cancer: mechanisms and clinical therapeutic perspectives
by: Xizi Li, et al.
Published: (2025-08-01)

Case report: A successful case of targeted immunotherapy for locally advanced pancreatic cancer under non-surgical conditions
by: Yuanbo Bi, et al.
Published: (2025-01-01)

Combined systemic immune-inflammatory index and prognostic nutritional index predicts the efficacy and prognosis of ES-SCLC patients receiving PD-L1 inhibitors combined with first-line chemotherapy
by: Yi Ge, et al.
Published: (2024-12-01)

Neoadjuvant chemoradiotherapy with or without PD-1/PD-L1 inhibitors in locally advanced rectal cancer: a systematic review and meta-analysis
by: Muhammad Ansab, et al.
Published: (2025-07-01)

Complete remission in PD-L1 high expression advanced gastric cancer patient with PD-L1 immunotherapy and chemotherapy integration treatment strategy: a case report
by: Xiaopeng Yu, et al.
Published: (2025-05-01)

Delta‐He as a Novel Predictive and Prognostic Biomarker in Patients With NSCLC Treated With PD–1/PD‐L1 Inhibitors
by: Green Hong, et al.
Published: (2025-04-01)

Optimizing Immunotherapy: The Synergy of Immune Checkpoint Inhibitors with Artificial Intelligence in Melanoma Treatment
by: Mohammad Saleem, et al.
Published: (2025-04-01)

TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives
by: Zhuohong Yan, et al.
Published: (2025-05-01)

Prognostic value of human papilloma virus (HPV) status and programmed cell death ligand 1 (PD-L1) status in oral tongue cancer
by: Mateusz Szewczyk, et al.
Published: (2024-11-01)

Survival and pathological response in pancreatic ductal adenocarcinoma after preoperative therapy with PD-1 blockade plus chemoradiotherapy followed by surgical resection
by: Elyar Abaydulla, et al.
Published: (2025-12-01)

Sex-Related Differences in the Immune System Drive Differential Responses to Anti-PD-1 Immunotherapy
by: Sonja Cotra, et al.
Published: (2024-11-01)

New model to predict survival in advanced pancreatic ductal adenocarcinoma patients by measuring GGT and LDH levels and monocyte count
by: Rocío del Campo-Pedrosa, et al.
Published: (2024-10-01)

Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors
by: Zhenzhen Fan, et al.
Published: (2020-05-01)

Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors
by: Wenke Li, et al.
Published: (2025-07-01)

Corrigendum: New model to predict survival in advanced pancreatic ductal adenocarcinoma patients by measuring GGT and LDH levels and monocyte count
by: Rocío del Campo-Pedrosa, et al.
Published: (2025-01-01)

The establishment of PD-1 inhibitor treatment prognosis model based on dynamic changes of peripheral blood indexes in patients with advanced lung squamous cell carcinoma
by: Yuyan Xie, et al.
Published: (2024-12-01)

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
by: Yizhou Zhang, et al.
Published: (2024-12-01)

Enhancing cancer care with improved checkpoint inhibitors
by: Vickram A S, et al.
Published: (2024-10-01)

Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends
by: Talaiti Tuergan, et al.
Published: (2025-12-01)

Efficacy of irreversible electroporation combined with immunotherapy versus irreversible electroporation alone in locally advanced pancreatic cancer: a propensity score-matched retrospective study
by: Pu Xi, et al.
Published: (2025-07-01)

Case report: Low-dose interleukin-2: a treatment of bullous pemphigoid with predominantly perifollicular blistering caused by PD-1/PD-L1 inhibitor
by: Yingyue Zhang, et al.
Published: (2024-12-01)

Thyroid Dysfunction After Intensity-Modulated Radiotherapy and PD⁃1 Inhibitor Treatment for Locally Advanced Nasopharyngeal Carcinoma
by: Shang K, et al.
Published: (2025-01-01)

PD-L1 levels, TP53 mutation profiles, and survival outcomes in pancreatic cancer differ by immune-nutritional status
by: Zheng Li, et al.
Published: (2025-04-01)

The expression and prognostic predictive value of PD-L2 in patients undergoing radical gastric cancer surgery
by: Xiuping Zhang, et al.
Published: (2025-12-01)

Association between smoking status, toxicity and survival in the checkpoint inhibitor immunotherapy
by: Anna Rudzińska, et al.
Published: (2024-11-01)

PD-1/PD-L1 immune checkpoint inhibitors in the treatment of unresectable locally advanced or metastatic triple negative breast cancer: a meta-analysis on their efficacy and safety
by: Zuxiu Wang, et al.
Published: (2024-10-01)

Immune checkpoint inhibitor outcomes and prognostic factors in gynecologic tract melanoma: a single-center analysis
by: Jianzhang Wang, et al.
Published: (2025-04-01)

Evaluation of the efficacy and predictive indicators of PD- 1 inhibitors combined with chemotherapy in advanced pancreatic cancer
by: Tiantian Zhang, et al.
Published: (2025-04-01)

An updated review of immunotherapy in esophageal cancer: PD-L1 footprint
by: Juan Yao, et al.
Published: (2024-05-01)

Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis
by: Wei Ren, et al.
Published: (2025-03-01)